Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity
Mesoblast Limited

ABN 68 109 431 870 Quarter ended ("current quarter")

31 December 2007

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (6 months) \$A'000
1.1	Receipts from customers:		<i>Φ1</i> 1 000
	Government commercial ready grant	0	124
1.2	• Payments for (a) staff costs	(159)	(512)
	(b) advertising and marketing	-	-
	(c) research and development	(refer 1.7 below)	(refer 1.7 below)
	(d) leased assets	-	-
	(e) other working capital	(239)	(575)
1.3	Dividends received		· · ·
1.4	Interest and other items of a similar nature received	168	342
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Other :		
	 commercialisation costs 	(610)	(2,026)
	(includes R&D and support costs)	× /	
	Net operating cash flows	(840)	(2,650)


⁺ See chapter 19 for defined terms.

		Current quarter \$A'000	Year to date (6 months) \$A'000
1.8	Net operating cash flows (carried forward)	(840)	(2,650)
1.9	Cash flows related to investing activities Payment for acquisition of: (a) businesses (item 5) (b) equity investments	(5.550)	(6.410)
	 (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 	(5,559)	(6,419) (25) (64)
1.10	 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 		
1.11 1.12 1.13	Loans to other entities Loans repaid by other entities Other (provide details if material)	449	(156) 449
	Net investing cash flows	(5,111)	(6,215)
1.14	Total operating and investing cash flows	(5,951)	(8,865)
1.15 1.16 1.17 1.18 1.19 1.20	Cash flows related to financing activities Proceeds from issues of shares, options, etc. Proceeds from sale of forfeited shares Proceeds from borrowings Repayment of borrowings Dividends paid Other (provide details if material)	13,597	13,597
	Net financing cash flows	13,597	13,597
	Net increase (decrease) in cash held	7,646	4,732
1.21 1.22	Cash at beginning of quarter/year to date Exchange rate adjustments to item 1.21	9,138 (2)	12,055 (5)
1.23	Cash at end of quarter	16,782	16,782

⁺ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(88)
1.25	Aggregate amount of loans to the parties included in item 1.11	-



Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

⁺ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Year to date (₆ months) \$A'000
4.1	Cash on hand and at bank	324	324
4.2	Deposits at call	3,863	3,863
4.3	Bank overdraft	-	-
4.4	Other (term deposits 30-90 days)	12,595	12,595
	Total: cash at end of quarter (item 1.23)	16,782	16,782

Acquisitions and disposals of business entities – N/A

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity		
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets		
5.5	Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:

...... Date: ...31 January 2008......

(Company secretary)

Print name:Kevin Hollingsworth.....

⁺ See chapter 19 for defined terms.

Notes

- 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
- 2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 itemised disclosure relating to acquisitions
 - 9.4 itemised disclosure relating to disposals
 - 12.1(a) policy for classification of cash items
 - 12.3 disclosure of restrictions on use of cash
 - 13.1 comparative information
- 3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

Item 1.9(b) – equity investment – A\$6,419,000 YTD

The equity investment relates to the following:

(a) On 23 November 2006 the shareholders at an Extraordinary General Meeting considered and passed the following resolution – "that pursuant to ASX Listing Rule 10.1, Chapter 2E of the Corporations Act 2001 (Cth) and for all other purposes approval is granted for the Company to invest up to Aus\$8.5 million in additional funds to subscribe for up to 425,000 further preference shares (designated "Series B Preferred") in Angioblast Systems Inc."

A total of \$6,419,000 has been paid to Angioblast under this agreement so far this year. A total of \$1,881k was paid in the last financial year under the same agreement. Therefore the total amount paid under this agreement is \$8,300k, leaving a remainder of \$200k still to be invested in furthering the technology under the agreement.

⁺ See chapter 19 for defined terms.